Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SDextran1
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Ophthalmic, Intravenous, Parenteral
01
Overview
SDextran1 is a sulfated dextran with a molecular weight of 1000 Da. It functions as a selective blocker of aldolase A (ALDOA), an enzyme known to promote the growth of hepatocellular carcinoma (HCC). By inhibiting ALDOA, SDextran1 has demonstrated significant anti-HCC effects both in vitro and in vivo.
Beyond the preview
Go deeper on SDextran1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SDextran1.